Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy

The novel coronavirus-2019 (COVID-19) has caused a global pandemic of historical proportions, infecting millions of people worldwide. Due to its high mortality rate and a paucity of clinical data, experimental therapies have been utilized with uncertain success and, unfortunately, poor outcomes. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Geisen, Will R., Berger, Justin, Schwartz, Chelsea, Reddy, Abhimanyu, Rai, Balaj, Wadih, George, Peck, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507983/
https://www.ncbi.nlm.nih.gov/pubmed/32983888
http://dx.doi.org/10.1016/j.idcr.2020.e00962
_version_ 1783585337259327488
author Geisen, Will R.
Berger, Justin
Schwartz, Chelsea
Reddy, Abhimanyu
Rai, Balaj
Wadih, George
Peck, Joshua
author_facet Geisen, Will R.
Berger, Justin
Schwartz, Chelsea
Reddy, Abhimanyu
Rai, Balaj
Wadih, George
Peck, Joshua
author_sort Geisen, Will R.
collection PubMed
description The novel coronavirus-2019 (COVID-19) has caused a global pandemic of historical proportions, infecting millions of people worldwide. Due to its high mortality rate and a paucity of clinical data, experimental therapies have been utilized with uncertain success and, unfortunately, poor outcomes. We describe a gentleman who was treated with experimental therapies and subsequently developed cytomegalovirus colitis and hypovolemic shock. Additionally, this case validates colonoscopy as a mode to rule out concurrent infectious etiologies causing diarrhea in COVID-19-positive patients.
format Online
Article
Text
id pubmed-7507983
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75079832020-09-23 Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy Geisen, Will R. Berger, Justin Schwartz, Chelsea Reddy, Abhimanyu Rai, Balaj Wadih, George Peck, Joshua IDCases Case Report The novel coronavirus-2019 (COVID-19) has caused a global pandemic of historical proportions, infecting millions of people worldwide. Due to its high mortality rate and a paucity of clinical data, experimental therapies have been utilized with uncertain success and, unfortunately, poor outcomes. We describe a gentleman who was treated with experimental therapies and subsequently developed cytomegalovirus colitis and hypovolemic shock. Additionally, this case validates colonoscopy as a mode to rule out concurrent infectious etiologies causing diarrhea in COVID-19-positive patients. Elsevier 2020-09-22 /pmc/articles/PMC7507983/ /pubmed/32983888 http://dx.doi.org/10.1016/j.idcr.2020.e00962 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Geisen, Will R.
Berger, Justin
Schwartz, Chelsea
Reddy, Abhimanyu
Rai, Balaj
Wadih, George
Peck, Joshua
Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy
title Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy
title_full Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy
title_fullStr Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy
title_full_unstemmed Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy
title_short Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy
title_sort cytomegalovirus enterocolitis secondary to experimental covid-19 therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507983/
https://www.ncbi.nlm.nih.gov/pubmed/32983888
http://dx.doi.org/10.1016/j.idcr.2020.e00962
work_keys_str_mv AT geisenwillr cytomegalovirusenterocolitissecondarytoexperimentalcovid19therapy
AT bergerjustin cytomegalovirusenterocolitissecondarytoexperimentalcovid19therapy
AT schwartzchelsea cytomegalovirusenterocolitissecondarytoexperimentalcovid19therapy
AT reddyabhimanyu cytomegalovirusenterocolitissecondarytoexperimentalcovid19therapy
AT raibalaj cytomegalovirusenterocolitissecondarytoexperimentalcovid19therapy
AT wadihgeorge cytomegalovirusenterocolitissecondarytoexperimentalcovid19therapy
AT peckjoshua cytomegalovirusenterocolitissecondarytoexperimentalcovid19therapy

Ejemplares similares